<DOC>
	<DOCNO>NCT00356408</DOCNO>
	<brief_summary>This open-label extension study design measure safety , efficacy , corticosteroid-sparing effect certolizumab pegol ( CDP870 ) patient moderate severe Crohn 's disease previously enrol C87059 ( COSPAR I , NCT00349752 ) .</brief_summary>
	<brief_title>Examining Long Term Safety , Efficacy , Corticosteroid-sparing Effect Certolizumab Pegol Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients previously enrol C87059 ( COSPAR I , NCT00349752 ) Subject withdrawn discontinue C87059 ( COSPAR I , NCT00349752 ) study specific condition Subject receive treatment study medication medication permit C87059 ( COSPAR I , NCT00349752 ) Subjects country certolizumab pegol authorize Crohn 's disease treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>CDP870</keyword>
	<keyword>certolizumab pegol</keyword>
	<keyword>Crohn 's Disease</keyword>
</DOC>